Skip to main content

Tender offer deadline in $4.3B Roche-Spark deal pushed back for a fifth time.

The proposed sale of the Philadelphia gene therapy pioneer continues to be delayed by ongoing regulatory reviews by the FTC and CMA.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.